ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2382

Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1928

Utilization of Rapid Telehealth Visits by Advanced Practice Providers for New Patients Referred to a Large Academic Practice with Low Suspicion for Rheumatologic Disease

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2192

Utilizing Electronic Health Record Pre-Consultation Data to Create a Predictive Algorithm for Diagnosis of Chronic Pediatric Rheumatic Conditions

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1874

Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2395

Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1970

Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis for Enthesitis

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 2412

Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2146

Validation of the Simple Calculated Osteoporosis Risk Estimation and Osteoporosis Self-assessment Tool Among People Aging with HIV in Peru

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2223

Validation Study in Early Rheumatoid Arthritis Patients of the Spanish Society of Rheumatology (SER)/Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Screening Criteria for Interstitial Lung Disease

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1901

Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1943

Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2098

Vitamin D Deficiency Is Associated with Progression of Radiographic Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study

Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2428

Vitamin-D Effect on SLE- Scoping Review

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1884

VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1937

Wellness and Burnout Among Pediatric Rheumatologists in North America- A 2024 CARRA Study

Health Services Research – ACR/ARP Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].